Unique ID issued by UMIN | UMIN000002886 |
---|---|
Receipt number | R000003521 |
Scientific Title | The Impact of Eicosapentaenoic Acid Pretreatment on Periprocedural Microcirculatory Damage in Patients Undergoing Percutaneous Coronary Intervention |
Date of disclosure of the study information | 2009/12/13 |
Last modified on | 2018/12/01 20:59:01 |
The Impact of Eicosapentaenoic Acid Pretreatment on Periprocedural Microcirculatory Damage in Patients Undergoing Percutaneous Coronary Intervention
The Impact of Eicosapentaenoic Acid Pretreatment on Periprocedural Microcirculatory Damage in Patients Undergoing Percutaneous Coronary Intervention
The Impact of Eicosapentaenoic Acid Pretreatment on Periprocedural Microcirculatory Damage in Patients Undergoing Percutaneous Coronary Intervention
The Impact of Eicosapentaenoic Acid Pretreatment on Periprocedural Microcirculatory Damage in Patients Undergoing Percutaneous Coronary Intervention
Japan |
Patients with stable angina pectoris who undergo percutaneous coronary intervention
Cardiology |
Others
NO
To evaluate the effect of eicosapentaenoic acid pretreatment on post-procedural microvascular damage by intracoronary pressure/temperature sensor-tipped guide wire.
Efficacy
Exploratory
Change in index of microcirculatory index
1)Absolute value of the CK-MB and high-sensitive troponin I measured at 8 and 24 hours after PCI
2)Absolute and percent changes of lipid profiles
3)Absolute and percent changes of high-sensitive CRP, VCAM-1, and MMP-9
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
No treatment
YES
Institution is not considered as adjustment factor.
Central registration
2
Treatment
Medicine |
pravastatin treatment (1800mg daily) 4 weeks before elective PCI
no pretreatment
20 | years-old | <= |
80 | years-old | > |
Male and Female
1)Stable angina pectoris
2)Culprit lesion involving 75% or more of the stenosis
3)Patients with dyslipidemia: LDL-cho >=100mg/dL and patients who are judged by the investigator as needing cholesterol lowering therapy
4)Patients providing written consent for participation in this clinical trial on their own volition after receiving a thorough explanation of the study
1)Target PCI lesion is left main coronary artery
2)Target PCI lesion is graft stenosis or in-stent restenosis
3)Patients on hemodialysis
4)Patients with acute coronary syndrome
5)Patients with contraindication of antiplatelet of anticoagulation drug
6)Patients with a history of hypersensitivity to any of the components of the product
7)Patients who are judged by the principal investigator to be ineligible for enrollment in the study
100
1st name | |
Middle name | |
Last name | Tohru Masuyama |
Hyogo College of Medicine
Cardiovascular Division
1-1 Mukogawa-cho, Nishinomiya-city, Hyogo 6638501 JAPAN
0798-45-6553
1st name | |
Middle name | |
Last name | Kenichi Fujii |
Hyogo College of Medicine
Cardiovascular Division
1-1 Mukogawa-cho, Nishinomiya-city, Hyogo 6638501 JAPAN
0798-45-6553
Cardiovascular Division, Hyogo College of Medicine
None
Self funding
NO
2009 | Year | 12 | Month | 13 | Day |
Unpublished
Completed
2009 | Year | 10 | Month | 30 | Day |
2009 | Year | 12 | Month | 01 | Day |
2009 | Year | 12 | Month | 13 | Day |
2018 | Year | 12 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003521
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |